City

Seoul (1)

Condition

Refractory Pediatric AML (2)

Relapsed Pediatric AML (2)

AML, Childhood (1)

CBFA2T3-GLIS2-positive Acute Myeloid Leukemia (1)

Refractory Pediatric Solid Tumor (1)

Relapsed Pediatric Solid Tumor (1)

Overall Status

Not yet recruiting (1)

Recruiting (1)

Sign in for free

Phase

phase 1 (1)

phase 2 (1)

Sponsor

Elucida Oncology (1)

Samsung Medical Center (1)

Collaborator

Ministry of Health, Republic of Korea (1)

Therapeutic Advances in Childhood Leukemia and Lymphoma (TACL) (1)

Study Documents

Intervention Type

drug (2)

procedure (1)

Funder Type

Industry (1)

Other (1)

Study Type

Interventional (2)

refractory pediatric aml

Showing 1 - 2 of 2

Trials per page:

STUDY

CONDITIONS

INTERVENTIONS

LOCATIONS

LAST UPDATED

CBFA2T3-GLIS2-positive Acute Myeloid Leukemia, AML, Childhood, Relapsed Pediatric AML Trial (ELU001)

Not yet recruiting

CBFA2T3-GLIS2-positive Acute Myeloid Leukemia
+3 more

ELU001

(no location specified)

Nov 14, 2022

Relapsed Pediatric Solid Tumor, Refractory Pediatric Solid Tumor, Relapsed Pediatric AML Trial in Seoul (CancerSCAN™,

Recruiting

Relapsed Pediatric Solid Tumor
+3 more

CancerSCAN™
+17 more

Seoul, Korea, Republic of

Samsung Medical Center

Mar 18, 2020